NEWS: Senzime reports from the Innovation Pavilion at The MedTech Conference
The MedTech Conference is the global summit for medical technology industry leaders and the largest annual gathering of medical technology professionals in North America. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and digital health technologies.
“We are proud to have been selected to display our cutting-edge technology at the Innovation Pavilion to a large portion of key opinion leaders from the US. This is really the place to be if you want to network and get access to decisionmakers in our field. We have established valuable contacts that can assist us on our journey towards product launch in the US”, says Lena Söderström, CEO at Senzime.
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com